profit from every ₹100 of sales.
₹0₹100
Aarti Pharmalabs
₹923.50+0.23% today
+21.9% in 1 year
1-year low ₹591.951-year high ₹975.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹47.93 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Aarti Pharmalabs sold, what it kept, and what it did with the cash.
Sales went from ₹19.4 billion in 2023 to ₹18.2 billion in 2026, with ₹1.75 billion of profit last year.
SalesProfit
Aarti Pharmalabs vs. similar companies
Aarti Pharmalabs grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Aarti Pharmalabs | 47.9× · Expensive | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Aarti Pharmalabs's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 19,360 | 18,155 | 21,151 | 18,194 | |
| 6,820 | 7,024 | 10,384 | 9,846 | |
| 2,795 | 3,128 | 3,775 | 2,981 | |
| 3,444 | 3,909 | 4,745 | 3,842 | |
| 1,935 | 2,169 | 2,724 | 1,747 | |
| 21.35 | 23.93 | 30.04 | 19.25 | |
| 35.2% | 38.7% | 49.1% | 54.1% | |
| 14.4% | 17.2% | 17.8% | 16.4% | |
| 10.0% | 11.9% | 12.9% | 9.6% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 22,440 | 25,821 | 29,064 | 34,817 |
| Cash | 121 | 236 | 67 | 85 |
| Total debt | 2,153 | 2,853 | 4,208 | 7,544 |
| Total liabilities | 6,855 | 8,251 | 9,165 | 13,571 |
| 15,585 | 17,570 | 19,899 | 21,246 | |
| 91 | 91 | 91 | 91 | |
| 11.9% | 11.7% | 12.1% | 7.3% | |
| 12.4% | 12.3% | 13.7% | 8.2% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,501 | 2,164 | 3,301 | 2,619 | |
| 1,197 | 1,988 | 4,439 | 4,483 | |
| 1,305 | 176 | -1,137 | -1,864 | |
| Dividends paid | 181 | 181 | 317 | 363 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 47.9×
- –
- –
- 2.7×
- 4.6×
- –
- 23.7×
- -2.2%
- 2.1%
- 0.4%
Profitability
- 54.1%
- 16.4%
- 9.6%
- –
- 7.3%
- 10.7%
- –
- –
- –
- –
Growth
- −2.0%
- −3.4%
- –
- –
- +0.0%
Financial health
- 1.9×
- 0.36
- –
- 6.0×
- 1.49
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 958
Top 30%of 888
Bottom 24%of 600
Bottom 13%of 889
Bottom 27%of 987
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
20.8% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
38No pass
Philip Fisher
29No pass
Peter Lynch
23No pass
Joel Greenblatt
5No pass
Charlie Munger
30No pass
Terry Smith
17No pass
Questions about Aarti Pharmalabs
Is Aarti Pharmalabs a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aarti Pharmalabs AI analysis
What does Aarti Pharmalabs do?
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Does Aarti Pharmalabs pay a dividend?
Yes. At today's price the dividend is 0.4% a year, about 21% of its yearly profit. In 2026 it paid out ₹363 million in dividends.
Is Aarti Pharmalabs stock halal?
Yes. Aarti Pharmalabs passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Aarti Pharmalabs stock done over the past year?
Up 21.9% over the past twelve months, to ₹923.50. It traded between ₹591.95 and ₹975.00 and is 5.3% below its high.
Who are Aarti Pharmalabs's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Aarti Pharmalabs's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.